STREAMER : STent Restenosis And MEdicaments Release

STREAMER : Stent Restenosis and Medicaments Release : Does Local Delivery of Paclitaxel be Safe and Efficient in Stenting of TransAtlantic InterSociety Consensus (TASC) Class C and D Femoropopliteal Artery Lesions

It is a pilot study to evaluate the feasibility and the efficiency of local delivery of paclitaxel after stenting of long femoropopliteal arterial lesions TASC C and D before the realization of a large randomized multicentric study. Patients concerned are in critical ischemia.

Inclusion Criteria:

• patients with critical ischemia of a lower limb with ankle pressure < 50 mmHg
• lesions TASC C and D of the superficial femoral or popliteal artery

Exclusion Criteria:

• patient allergic to paclitaxel
• patient with a cancer, a neutropenia, with immunosuppressor medicament or chemotherapy
• patient with contraindication to take 2 anti-aggregants platelets